Exchange: NASDAQ·Updated 07:32 PM EST

ANIK News

News
all
press releases
Anika Therapeutics' (ANIK) "Buy" Rating Reiterated at B. Riley Financial
B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday...
MarketBeat
Anika Therapeutics' (ANIK) "Buy" Rating Reiterated at B. Riley Financial
B. Riley Financial reissued a "buy" rating and set a $17.00 price objective (down from $23.00) on shares of Anika Therapeutics in a research note on Monday...
MarketBeat
More News
Anika (ANIK) delivered earnings and revenue surprises of +70.59% and +3.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Regenxbio (RGNX) delivered earnings and revenue surprises of +54.07% and -4.53%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
Zacks
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Zacks
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
Zacks
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
Zacks
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Zacks
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Zacks
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Zacks

Advertisement|Remove ads.